Takeda Pharmaceutical (TAK) Gross Profit (2017 - 2026)

Takeda Pharmaceutical's Gross Profit history runs 10 years deep, the most recent figure standing at $4.4 billion for Q1 2026.

• In Q1 2026, Gross Profit fell 18.37% year-over-year to $4.4 billion; the TTM figure through Mar 2026 stood at $30.1 billion (down 1.12% YoY), while the FY2026 annual figure was $19.5 billion, up 261.69% from the prior year.
• Gross Profit was $4.4 billion for Q1 2026 at Takeda Pharmaceutical, down from $4.5 billion in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $15.8 billion in Q3 2025 to a low of $4.4 billion in Q1 2026.
• Historically, Gross Profit has averaged $6.9 billion across 5 years, with a median of $5.3 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Gross Profit soared 203.91% in 2022, then tumbled 66.22% in 2023.
• A 5-year view of Gross Profit shows it stood at $4.6 billion in 2022, then decreased by 1.57% to $4.5 billion in 2023, then fell by 2.77% to $4.4 billion in 2024, then gained by 1.67% to $4.5 billion in 2025, then fell by 1.79% to $4.4 billion in 2026.
• The last three Gross Profit figures came in at $4.4 billion (Q1 2026), $4.5 billion (Q4 2025), and $15.8 billion (Q3 2025), per Business Quant data.